pain-neuropathic-spinifex-27.html
Novo Annual Report 2015
28 / 72
d uring 2015,
novo
added five public and 12 private companies to its venture portfolio. in most of the private
financing
s, we played a key role as lead or co-lead investors. our new portfolio companies develop therapies for a variety of indications, including migraine, cancer immunotherapy, cns, ophthalmology, glaucoma, immune diseases and anti- infective therapies. except for one, all the new companies are located in the us. anti-infectives nabriva therapeutics (nasdaq:nbrv) develops novel anti-infective agents. the lead product candidate, lefamulin is in phase 3 for the treatment of community-acquired bacterial pneumonia.
novo
invested in the
company
?s ipo. cancer immunotherapy corvus pharmaceuticals develops drugs that reprogramme t cells to restore the immune balance needed for tumour destruction.
novo
participated in corvus? two
financing
in 2015. encarta therapeutics plans to develop novel t-cell therapies for cancer.
novo
was a co-investor in encarta?s
financing
. merus closed a
financing
in august that was co-led by
novo
. the
company
develops fully human bi-specific antibodies for various oncology indications. nkarta therapeutics is focused on developing natural killer (nk) cell-based therapies for use in the treatment of cancers.
novo
co-lead the initial
financing
of the
company
. unum therapeutics develops antibody-coupled t-cell receptor technology for use in cellular immunotherapies for cancer.
novo
invested in its recent
financing
. vasculox develops a portfolio of anti-cd47 therapeutic antibodies for the treatment of cancer and pulmonary hypertension.
novo
invested in its recent
financing
. cancer supportive care galera therapeutics closed a
financing
in october that was led by
novo
. galera therapeutics is a clinical-stage
company
with a lead product focused on radiation-induced mucositis. cns colucid pharmaceuticals (nasdaq:clcd) develops innovative therapies for cns disorders and has initiated its first phase 3 pivotal trial to confirm lasmiditan?s safety and efficacy.
novo
invested in the
company
?s ipo. e-scape bio closed a
financing
in august that was co-lead by
novo
. the
company
develops a pipeline of apoe4 structure correctors for the treatment of neurodegenerative diseases, including alzheimer?s disease. immune diseases kanyos bio is a spin-out from anokion. the
company
focuses on autoimmune diseases (e.g. celiac disease and type 1 diabetes) under an option deal with astellas. ra pharmaceuticals closed a
financing
in july that was co-led by
novo
. the
company
focuses on developing peptide-based drugs for treatment of diseases of complement dysregulation. medical devices glaukos (nasdaq:gkos) is focused on the commercialisation of medical devices to treat glaucoma.
novo
invested in the
company
?s ipo. invuity (nasdaq:ivty) is pioneering and commercialising the use of advanced photonics to provide surgeons with improved direct visualisation of surgical cavities during minimally invasive surgery.
novo
invested in the
company
?s ipo. penumbra (nyse:pen) develops and commercialises innovative medical devices primarily for the neuro and peripheral vascular markets.
novo
invested in the
company
?s ipo. procept biorobotics closed a
financing
in july that was led by
novo
. the
company
is developing a new treatment for benign prostate hyperplasia based on robot-controlled water ablation of prostate tissue. unchained labs closed a
financing
in february that was led by
novo
. the
company
develops and markets life science tools for analysing protein stability. introducing the class of 2015
novo
a/s 28
novo
ventures
2015-million-usd-29.html
